CALGARY, Feb. 19, 2021 – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on delivering innovative psychedelic-assisted therapies internationally, revealed details today about the first Psychedelic Journey Center in Canada which will be located in central Alberta.

The company will own and operate the private wellness center that is nestled within a retreat setting within a sprawling forest and nature, positioned approximately 2 hours from both Calgary and Edmonton. ATMA Creekside will provide a convenient destination in which clients will be able to experience a range of healing and transformational modalities as part of multi-day experiences, ceremonies, and retreats.

David Harder, Co-CEO of ATMA, said: “Creekside Journey Center begins the exciting rollout of our plans to create immersive retreat-style Journey Centers across Canada and beyond. Our aim is to position ATMA as the disruptor in a psychedelic renaissance that is so often focused on up-scaling the therapy.”

Rather than focusing on patient through-put and optimizing to move as many people through medicine work as quickly as possible, the company says that its goal is to provide deeply immersive protocols that bring people inward and find life-long healing. The trend in psychedelic therapy appears to be in proprietary molecules and processes eligible to be patented or trademarked, but Harder points out that ATMA wants to provide a different experience.

“ATMA will be known for finding a place you can connect, find healing, and discover community,” he said.  “Our philosophy is that these deep inner medicine sessions are not best suited in a clinical appointment where only a few hours are allotted in the midst of a busy day and lifestyle. “

Harder explained that the company’s protocols are designed to be experienced over a number of weeks, and include, beyond the counselling and medicine work, time to connect with nature and others on a similar path. “This particular property at Creekside has a special energy to it, and with the incredible forest and relaxing creek that flows throughout the expansive property, we believe it’s going to provide a magical space that will provide clients meaningful experiences and healing.”

When the property opens this spring, it will provide full-service programs that include well-appointed cottages and suites, holistic and organic food prepared by certified chefs, and leading-edge psychedelic medicine therapy and protocols. The individual therapy sessions will be combined with group work which will intentionally provide both the individual processes needed to overcome mental health challenges as well as group journey opportunities where community can be fostered.  A customized program of individual therapy sessions will occur both before and after the medicine work done at the Journey Center, allowing each client to be fully prepared for their experience and to have the support before and after their Journey Center visit.

“Our goal is to create an ultra-comfortable, safe and peaceful environment where the only thing a client needs to focus on is their own work and healing in a community of safe spaces and community support,” said Harder. He explained that the company’s vision is not to create a portfolio of medical-style psychedelic clinics located in busy urban centers. “Our business plan is to create nature-inspired destinations where a client can remove themselves from daily life for a few days or a week or more. We believe it’s important they have space and time to really focus on doing the deep work that will provide shifts and changes that are sustainable and life-changing.”

ATMA was the first private company in Canada to legally conduct psychedelic-assisted therapy using psilocybin under a Section 56 Exemption that was granted to a palliative patient by Health Canada. Additional patients who have recently obtained Section 56 Exemptions are also scheduled to undergo legal psychedelic therapy with ATMA next week.

Greg Habstritt, President of ATMA, said: “While we remain optimistic that Health Canada will continue to increase access to psychedelic therapy, we’re mindful that the timelines are not certain and that it will take some time before mainstream access to this medicine exists.”

He suggested that because of this, ATMA’s business model will allow the generation of immediate revenue and cash flow from more traditional retreat services while the company continues to work within the Health Canada guidelines and regulations.

“We’re a bit different in the industry, because we’re not building clinics out designed exclusively for psychedelic therapy and then waiting for the legislation to change.  We’ll be operating profitable Journey Centers immediately, with the ability to introduce and expand a range of psychedelic medicines and related services as they become accessible and legal.”

Added Harder: “Today has special meaning to me because this is the realization of a vision that I’ve held for 5 years – to have a special environment in which this medicine work can be done. 

The acceleration of awareness and acceptance of psychedelics in the health care and medicine arenas over that time has been extraordinary to witness. In the end, what matters most is that those who are suffering and would benefit from this medicine get access to it as soon as possible.”

More News and Media:

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Is Training in Psychedelics Worth It?

Let’s start with a brief review of psychedelics, including what they are and how they differ from conventional Western medicine. There are many substances under the umbrella of psychedelics; the common ones are: Psilocybin (the active ingredient in magic mushrooms)  LSD (lysergic acid diethylamide) Ibogaine (the active ingredient in iboga) Mescaline (the active ingredient in

ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From COVID-19-Related Mental Wellness Challenges.

CALGARY, AB, May 10, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of its innovative psychedelic-assisted therapy solutions, announced the submission of its N-500 Phase II Psilocybin Clinical Trial to Health Canada today. This trial is aimed at studying the potential relief of COVID-19-associated mental health concerns in healthcare professionals, as well

Scroll to Top